|
|
|
|
Contact urticaria to raw potato
(Click the title below to leave the MDLinx Network and go to the Journal's Website) Dermatology Online Journal, 06/25/09 Print Save in My Library Free Full Text Lagran ZMD et al.- Although potatoes represent a large part of diets...
|
|
|
Levetiracetam Induced Interstitial Nephritis and Renal Failure
Save in My Library Free Abstract Hurwitz KA et al.- A 17-year-old girl who had started on levetiracetam because of new onset partial complex seizures developed acute renal failure and biopsy-confirmed interstitial nephritis 10 days after...
|
|
|
EMEA grants Clinuvel new orphan drug designation Committee for Orphan Medical Products (COMP) issues positive
Melbourne, Australia, 18th June, 2009 --Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is pleased to announce that afamelanotide, its photoprotective drug, has been granted Orphan Medicinal Product (OMP) designation...
|
|
|
Knocking The Wind Out Of Asthmatics: Help From Hippocrates
Last week the FDA knocked the wind out of asthmatics by requesting the manufacturers of Singulair, a popular leukotriene blocking asthma and allergy drug, to upgrade their warning against psychotic side effects.Further respiratory...
|
|
|
Knocking the Wind Out of Asthmatics: Help from Hippocrates
Asthma and allergy sufferers have an alternative to Singulair and Zicam - The ALCAT Test WARSAW, Poland, June 22 /PRNewswire/ -- Last week the FDA knocked the wind out of asthmatics by requesting the manufacturers of Singulair, a popular...
|
|
|
Knocking the Wind Out of Asthmatics: Help from Hippocrates
Asthma and allergy sufferers have an alternative to Singulair and Zicam - The ALCAT Test WARSAW, Poland, June 22 /PRNewswire/ -- Last week the FDA knocked the wind out of asthmatics by requesting the manufacturers of Singulair, a popular...
|
|
|
Knocking the Wind Out of Asthmatics: Help from Hippocrates
Asthma and allergy sufferers have an alternative to Singulair and Zicam - The ALCAT Test WARSAW, Poland, June 22 /PRNewswire/ -- Last week the FDA knocked the wind out of asthmatics by requesting the manufacturers of Singulair, a popular...
|
|
|
Knocking the Wind Out of Asthmatics: Help from Hippocrates
Asthma and allergy sufferers have an alternative to Singulair and Zicam - The ALCAT Test WARSAW, Poland What's an allergy sufferer to do?The manufacturers of the ALCAT Test, a food intolerance test, suggest going back to Hippocrates'...
|
|
|
EMEA Grants Clinuvel New Orphan Drug - For Solar Urticaria - Designation
Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is pleased to announce that afamelanotide, its photoprotective drug, has been granted Orphan Medicinal Product (OMP) designation by the European Medicines Agency (EMEA)...
|
|
|
Update Module 1482: Drug-induced skin reactions
When faced with a skin complaint, how can you tell if its drug-induced?Skin reactions caused by medicines can be difficult to distinguish from normal skin conditions, so find out if the problem coincided with new medication? Most drug...
|
|
|
Clinuvel's drug gets OMP status in Europe to treat solar urticaria
: Australia's Clinuvel Pharmaceuticals said that its photoprotective drug, afamelanotide, has been granted Orphan Medicinal Product (OMP) designation by the European Medicines Agency (EMEA) for the treatment of solar urticaria (SU).
|
|
|
Clinuvel awarded orphan drug status by EU
Clinuvel Pharmaceuticals has received Orphan Medical Product (OMP) designation by the European Medicines Agency (EMEA) for its drug, afamelanotide, for the treatment of solar urticaria (SU).OMP designation provides regulatory...
|
|
|
Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20 mg
Today in Derm Allergy/Immunology...Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20 mg.
|
|
|
Product news (13 June 2009)
Eye drop suspension.Non-steroidal anti-inflammatory pro-drug. Prevention and treatment of postoperative pain and inflammation associated with cataract surgery. In adults one drop in the conjunctival sac of the affected eye(s) three...
|
|
|
New antihistamine launched
Rupatadine (Rupafin), a second-generation antihistamine, has been launched by GlaxoSmithKline.Rupatidine is a long acting histamine antagonist with selective peripheral H1-receptor antagonist activity for the treatment of allergic...
|
|
|
Acute Urticaria and Angioedema: Diagnostic and Treatment Considerations
Today in Derm Allergy/Immunology...Acute Urticaria and Angioedema: Diagnostic and Treatment Considerations.
|
|
|
Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in
Clinical Data Presented at the 2009 ASCO Meeting INDIANAPOLIS, May 30 /PRNewswire/ -- Semafore Pharmaceuticals, Inc., a privately held cancer drug discovery and development company, today presented data from a Phase I clinical trial of its...
|
|
|
Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in
Clinical Data Presented at the 2009 ASCO Meeting INDIANAPOLIS, May 30 /PRNewswire/ -- Semafore Pharmaceuticals, Inc., a privately held cancer drug discovery and development company, today presented data from a Phase I clinical trial of its...
|
|
|
Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in
Clinical Data Presented at the 2009 ASCO Meeting ) INDIANAPOLIS, May 30, 2009 /PRNewswire via COMTEX/ -- Semafore Pharmaceuticals, Inc., a privately held cancer drug discovery and development company, today presented data from a Phase I...
|
|
|
Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in
Clinical Data Presented at the 2009 ASCO Meeting INDIANAPOLIS, May 30 /PRNewswire/ -- Semafore Pharmaceuticals, Inc., a privately held cancer drug discovery and development company, today presented data from a Phase I clinical trial of its...
|
|
|
Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in
Clinical Data Presented at the 2009 ASCO Meeting INDIANAPOLIS, May 30 /PRNewswire/ -- Semafore Pharmaceuticals, Inc., a privately held cancer drug discovery and development company, today presented data from a Phase I clinical trial of its...
|
